Companies / Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc.
Nasdaq: XLOCIK 1840233WALTHAM, MA
Financials · FY2025
Ownership
5.8M shares outstanding
Ownership
| Insiders | 6.91% | 399,809 |
| 10%+ / strategic | 251.06% | 14,517,678 |
| Institutions | 4.01% | 231,850 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (single-class filing figure). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 7
View all →| Insider | % of shares | Shares |
|---|---|---|
Russo ReneCEOPRESIDENT AND CEO · Director | 5.63% | 325,422 |
Luptakova KatarinaCHIEF MEDICAL OFFICER | 0.58% | 33,250 |
Frankenfield Christopher JamesChief Financial Officer | 0.43% | 24,766 |
Shannon James SamuelDirector | 0.17% | 10,000 |
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | 0.11% | 6,371 |
Blanchard Cheryl RDirector | — | — |
Gilead Sciences, Inc.10% owner | — | — |
Institutional holders 7
View all →| Holder | Value | % of shares |
|---|---|---|
| $1.02M | 1.83% | |
| $416.9K | 0.86% | |
| $312.8K | 0.64% | |
| $127.5K | 0.23% | |
| $83.9K | 0.15% | |
| $1.0K | <0.01% | |
| $143 | 0.29% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | Merck & Co., Inc. 13F manager | New | Common Stock | $1.02M | +106K | 105,982 1.83% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | New | Common Stock | $416.9K | +50K | 49,566 0.86% of shares | low |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | New | Common Stock | $312.8K | +37K | 37,197 0.64% of shares | low |
| Q2 2026 as of | State Street Corporation 13F manager | New | Common Stock | $127.5K | +13K | 13,311 0.23% of shares | low |
| Q2 2026 as of | BlackRock, Inc. 13F manager | New | Common Stock | $83.9K | +9K | 8,757 0.15% of shares | low |
| Q1 2026 as of | Royal Bank of Canada 13F manager | New | Common Stock | $1.0K | +91 | 91 <0.01% of shares | low |
| Q1 2026 as of | Gsa Capital Partners LLP 13F manager | New | Common Stock | $143 | +17K | 16,946 0.29% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Bain Capital Life Sciences Fund II, L.P. | Passive13G/A | — |
| Gilead Sciences, Inc. | Passive13G/A | — |
| Frazier Life Sciences Public Fund, L.P. | Passive13G/A | — |
| Stempoint Capital LP | Passive13G/A | — |
| Orbimed Advisors LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| XLO | Common Stock | 98422T209 |
| XLO | — | 28422T209 |